The study included 14 paediatric EoE patients aged 4-19 years, whose oesophageal biopsies were analysed before and after dupilumab treatment [1]. Histologic remission was defined by a peak eosinophil count (PEC) of less than 15 on follow-up biopsy. The biopsies were assessed using both traditional pathologist analysis and a validated AI model (Aiforia Technologies) for quantitative analysis of histopathologic features. The primary endpoints evaluated were PEC, EoE histology score (EoE-HSS), and improvements in basal zone hyperplasia (BZH) and dilated intercellular spaces (DIS). Secondary endpoints included lymphocyte counts and correlation of histologic changes with endoscopic reference scores (EREFS).
Of the 14 patients, 10 achieved histologic remission, showing a median decrease of 79.3% in PEC by AI analysis and 93.4% in the average eosinophil count per 0.24mmÂČ. Improvements were also observed in BZH (56.7%) and DIS (45.6%) in those who achieved remission. Additionally, a 30.3% decrease in peak lymphocyte count was noted in patients in remission, while those not in remission showed a 20.4% increase. Correlation analysis for all patients indicated a moderate correlation between EREFS changes and AI PEC changes, and a weaker correlation between EREFS changes and DIS AI changes.
The study confirms that dupilumab improves EoE-related histologic findings in paediatric patients, with AI-based quantitative assessments providing results comparable to traditional pathologist evaluations. These findings highlight the potential of dupilumab as an effective treatment for EoE, offering a promising option for improving patient outcomes.
- Hopson P, et al. Quantitative assessment of dupilumab treatment in pediatric patients characterized by an artificial intelligence analysis of histopathologic features of eosinophilic esophagitis. Sa2054, DDW 2024, 18â21 May, Washington, DC, USA.
Medical writing support was provided by Federica Angius.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF Next Article
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity »
« Meet the Trialist: Innovating cardiac monitoring with MONITOR-HF Next Article
Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity »
Table of Contents: DDW 2024
Featured articles
GALAXI 2 & 3: Guselkumab proves efficacy in Crohnâs disease
Online First
PREEMPT CRC: Blood-based CRC screening test shows promise
COX-2 inhibitors show promise in reducing the severity of acute pancreatitis
QUASAR maintenance study: Guselkumab effective and safe for UC
New cable-transmission capsule endoscopy shows high accuracy in detecting upper GI lesions
REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
STARS: Apraglutide shows efficacy in patients with SBS-IF
GALAXI 2 & 3: Guselkumab proves efficacy in Crohnâs disease
Quality-of-life assessment in children with eosinophilic oesophagitis
Related Articles
June 14, 2022
Octreotide therapy beats standard of care in GIADs
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com